2026. AN IN-SILICO STUDY OF ANDALIMAN (Zanthoxylum acanthopodium DC.) AS AN ANTICANCER AGENT AGAINST TYROSINE KINASE ENZYME INHIBITION USING THE DOCKING METHOD: IN SILICO MOLECULAR DOCKING STUDY OF ACTIVE COMPOUNDS FROM ANDALIMAN (Zanthoxylum acanthopodium DC.) AGAINST TYROSINE KINASE ENZYME AS AN ANTICANCER AGENT. Forte Journal. 6, 1 (July 2026), 348–372. DOI:https://doi.org/10.51771/fj.v6i1.2155.